Janney Montgomery Scott’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,639
| Closed | -$210K | – | 3184 |
|
|
2026
Q1 | $210K | Sell |
9,639
-120
| -1% | -$2.32K | ﹤0.01% | 2609 |
|
|
2025
Q4 | $210K | Sell |
9,759
-33,309
| -77% | -$702K | ﹤0.01% | 2786 |
|
|
2025
Q3 | $830K | Buy |
43,068
+14,325
| +50% | +$255K | ﹤0.01% | 1828 |
|
|
2025
Q2 | $492K | Buy |
28,743
+15,882
| +123% | +$678K | ﹤0.01% | 2013 |
|
|
2025
Q1 | $821K | Buy |
+12,861
| New | +$1.35M | ﹤0.01% | 1669 |
|
|
2024
Q3 | – | Sell |
-1,388
| Closed | -$219K | – | 2837 |
|
|
2024
Q2 | $219K | Buy |
+1,388
| New | +$178K | ﹤0.01% | 2400 |
|
|
2023
Q4 | – | Sell |
-22,584
| Closed | -$2.74M | – | 2749 |
|
|
2023
Q3 | $2.74M | Buy |
22,584
+20,566
| +1,019% | +$2.32M | 0.01% | 901 |
|
|
2023
Q2 | $231K | Sell |
2,018
-183
| -8% | -$23.6K | ﹤0.01% | 2382 |
|
|
2023
Q1 | $303K | Sell |
2,201
-1,548
| -41% | -$201K | ﹤0.01% | 2044 |
|
|
2022
Q4 | $486K | Buy |
+3,749
| New | +$434K | ﹤0.01% | 1793 |
|
|
2022
Q2 | – | Sell |
-3,253
| Closed | -$254K | – | 2436 |
|
|
2022
Q1 | $254K | Sell |
3,253
-161
| -5% | -$12.3K | ﹤0.01% | 1972 |
|
|
2021
Q4 | $307K | Buy |
3,414
+638
| +23% | +$54.5K | ﹤0.01% | 1985 |
|
|
2021
Q3 | $257K | Sell |
2,776
-1,558
| -36% | -$120K | ﹤0.01% | 2042 |
|
|
2021
Q2 | $337K | Buy |
4,334
+380
| +10% | +$28.8K | ﹤0.01% | 1853 |
|
|
2021
Q1 | $295K | Sell |
3,954
-511
| -11% | -$47.2K | ﹤0.01% | 1862 |
|
|
2020
Q4 | $761K | Sell |
4,465
-333
| -7% | -$49.3K | ﹤0.01% | 1323 |
|
|
2020
Q3 | $674K | Sell |
4,798
-163
| -3% | -$24.8K | ﹤0.01% | 1283 |
|
|
2020
Q2 | $795K | Buy |
4,961
+117
| +2% | +$15.9K | 0.01% | 1152 |
|
|
2020
Q1 | $474K | Sell |
4,844
-468
| -9% | -$53.5K | ﹤0.01% | 1248 |
|
|
2019
Q4 | $685K | Buy |
5,312
+382
| +8% | +$38.6K | ﹤0.01% | 1271 |
|
|
2019
Q3 | $371K | Buy |
4,930
+852
| +21% | +$101K | ﹤0.01% | 1561 |
|
|
2019
Q2 | $620K | Buy |
4,078
+109
| +3% | +$13.2K | ﹤0.01% | 1305 |
|
|
2019
Q1 | $473K | Buy |
3,969
+1,302
| +49% | +$167K | ﹤0.01% | 1424 |
|
|
2018
Q4 | $291K | Sell |
2,667
-410
| -13% | -$51.3K | ﹤0.01% | 1577 |
|
|
2018
Q3 | $497K | Buy |
3,077
+225
| +8% | +$30.8K | ﹤0.01% | 1454 |
|
|
2018
Q2 | $377K | Sell |
2,852
-4,068
| -59% | -$384K | ﹤0.01% | 1538 |
|
|
2018
Q1 | $513K | Sell |
6,920
-9,587
| -58% | -$639K | 0.01% | 1321 |
|
|
2017
Q4 | $918K | Buy |
16,507
+6,062
| +58% | +$321K | 0.01% | 984 |
|
|
2017
Q3 | $474K | Buy |
+10,445
| New | +$417K | 0.01% | 1285 |
|
|
2017
Q1 | – | Sell |
-16,246
| Closed | -$446K | – | 1799 |
|
|
2016
Q4 | $446K | Buy |
+16,246
| New | +$652K | 0.01% | 1131 |
|
Other funds holding SRPT
EAM
Janney Montgomery Scott's SRPT Position: Q2 2026 in Review
Janney Montgomery Scott sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 9,639 shares — an estimated $210K sold.
Janney Montgomery Scott first reported a position in SRPT in Q4 2016 and held it in 30 quarters. The position peaked at $2.74M in Q3 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Janney Montgomery Scott reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
- Janney Montgomery Scott sold 9,639 Sarepta Therapeutics shares in Q2 2026, an estimated $210K.
- Janney Montgomery Scott first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 30 quarters.
- Janney Montgomery Scott's Sarepta Therapeutics position peaked at $2.74M in Q3 2023.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.